Patents by Inventor Matthew J. Scanlan

Matthew J. Scanlan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8252903
    Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: August 28, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Cynthia H. Scanlan, legal representative, Sang-Yull Lee, Lloyd J. Old
  • Publication number: 20110177079
    Abstract: The invention relates to cancer-testis antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of novel cancer-testis (CT) antigens.
    Type: Application
    Filed: September 8, 2005
    Publication date: July 21, 2011
    Applicants: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Yao-Tseng Chen, Lloyd J. Old, Andrew J.G. Simpson, Victor C. Jongeneel, Matthew J. Scanlan, Cynthia H. Scanlan
  • Publication number: 20100172910
    Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
    Type: Application
    Filed: January 6, 2010
    Publication date: July 8, 2010
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Matthew J. Scanlan, Cynthia H. Scanlan, Sang-Yull Lee, Lloyd J. Old
  • Patent number: 7662917
    Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: February 16, 2010
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Cynthia H. Scanlan, legal representative, Sang-Yull Lee, Lloyd J. Old
  • Patent number: 7560537
    Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: July 14, 2009
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Sang-Yull Lee, Lloyd J. Old
  • Publication number: 20080089888
    Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
    Type: Application
    Filed: September 30, 2003
    Publication date: April 17, 2008
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Cynthia H. Scanlan, Sang-Yull Lee, Lloyd J. Old
  • Patent number: 7335467
    Abstract: The invention provides methods for diagnosing cancer including breast cancer, based on the identification of certain breast cancer-associated polypeptides as antigens that elicit immune responses in breast cancer. The identified antigens can be utilized as markers for diagnosing breast cancer, and for following the course of treatment of breast cancer.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: February 26, 2008
    Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc., Memorial Sloan-Kettering Cancer Center
    Inventors: Matthew J. Scanlan, Ivan Gout, Elisabeth Stockert, Lloyd J. Old, Ali Gure, Yao-Tseng Chen
  • Patent number: 7314721
    Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in small cell lung cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with small cell lung cancer. The invention provides, among other things, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided.
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: January 1, 2008
    Assignees: Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York Hospital-Cornell Medical Center
    Inventors: Ali O. Gure, Elisabeth Stockert, Matthew J. Scanlan, Dirk Jager, Lloyd J. Old, Yao-Tseng Chen
  • Patent number: 6982316
    Abstract: Various molecules associated with disorders such as cancer are disclosed. The invention also discloses diagnostic aid therapeutic methods based upon these molecules, as well as compositions for stimulating an immune response and methods for identifying cancer-associated nucleic acid and polypeptide molecules.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: January 3, 2006
    Assignees: Ludwig Institute for Cancer Research, The New York Hospital-Cornell Medical Center
    Inventors: Matthew J. Scanlan, Yao-Tseng Chen, Elisabeth Stockert, Lloyd J. Old
  • Patent number: 6794501
    Abstract: The invention provides methods for diagnosing cancer including colon cancer, based on the identification of certain colon cancer-associated polypeptides as antigens that elicit immune responses in colon cancer. The identified antigens can be utilized as markers for diagnosing colon cancer, and for following the course of treatment of colon cancer.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: September 21, 2004
    Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Yao-Tseng Chen, Lloyd J. Old, Matthew J. Scanlan, Elisabeth Stockert
  • Publication number: 20040126808
    Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in small cell lung cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with small cell lung cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided.
    Type: Application
    Filed: January 20, 2004
    Publication date: July 1, 2004
    Inventors: Ali O. Gure, Elisabeth Stockert, Matthew J. Scanlan, Dirk Jager, Lloyd J. Old, Yao-Tseng Chen
  • Publication number: 20040063101
    Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
    Type: Application
    Filed: September 30, 2002
    Publication date: April 1, 2004
    Inventors: Matthew J. Scanlan, Sang-Yull Lee, Lloyd J. Old
  • Patent number: 6686147
    Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in testis cells using antisera from seminoma patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with a variety of cancers. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: February 3, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Ali Gure, Lloyd J. Old, Yao-Tseng Chen, Barbara Williamson
  • Publication number: 20030165834
    Abstract: The invention provides methods for diagnosing cancer including colon cancer, based on the identification of certain colon cancer-associated polypeptides as antigens that elicit immune responses in colon cancer. The identified antigens can be utilized as markers for diagnosing colon cancer, and for following the course of treatment of colon cancer.
    Type: Application
    Filed: May 4, 2001
    Publication date: September 4, 2003
    Inventors: Yao-Tseng Chen, Lloyd J. Old, Matthew J. Scanlan, Elisabeth Stockert
  • Publication number: 20030108888
    Abstract: The invention provides methods for diagnosing cancer including breast cancer, based on the identification of certain breast cancer-associated polypeptides as antigens that elicit immune responses in breast cancer. The identified antigens can be utilized as markers for diagnosing breast cancer, and for following the course of treatment of breast cancer.
    Type: Application
    Filed: May 15, 2002
    Publication date: June 12, 2003
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Ivan Gout, Elisabeth Stockert, Lloyd J. Old, Ali Gure, Yao-Tseng Chen
  • Publication number: 20030044813
    Abstract: Cancer-testis (CT) antigens have been identified by screening public databases for transcripts that are expressed in tumor tissues and a limited set of normal tissues, or by screening for genes that are expressed in cancer and testis tissues (but not other normal tissues). The invention relates to nucleic acids and encoded polypeptides which are CT antigens expressed in patients afflicted with cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided.
    Type: Application
    Filed: January 22, 2002
    Publication date: March 6, 2003
    Inventors: Lloyd J. Old, Matthew J. Scanlan, Yao-Tseng Chen
  • Patent number: 6517837
    Abstract: Various molecules associated with disorders such as cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules, as well as compositions for stimulating an immune response and methods for identifying cancer-associated nucleic acid and polypeptide molecules.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: February 11, 2003
    Inventors: Matthew J. Scanlan, Yao-Tseng Chen, Elisabeth Stockert, Lloyd J. Old
  • Publication number: 20030023057
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses.
    Type: Application
    Filed: October 11, 2001
    Publication date: January 30, 2003
    Inventors: Ali O. Gure, Ozlem Tureci, Ugur Sahin, Solam Tsang, Matthew J. Scanlan, Alexander Knuth, Michael Pfreundschuh, Lloyd J. Old, Yao-Tseng Chen
  • Patent number: 6440663
    Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: August 27, 2002
    Assignees: Ludwig Institute for Cancer Research, The New York Hospital-Cornell Medical Center
    Inventors: Matthew J. Scanlan, Elisabeth Stockert, Yao-Tseng Chen, Lloyd J. Old, Elke Jager, Alex Knuth
  • Patent number: 6403373
    Abstract: Various molecules associated with cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: June 11, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Yao-Tseng Chen, Elisabeth Stockert, Lloyd J. Old